貴州三力(603439.SH):開喉劍系列產品目前在處方端和OTC端的佔比大概在5:5
格隆匯1月19日丨貴州三力(603439.SH)近日在接待機構投資者調研時表示,開喉劍噴霧劑(兒童型)因為09年就進入了國家醫保目錄,因此在處方端佈局較早,目前在二級以上有兒科的醫院和兒童專科醫院覆蓋率較高,百強連鎖也已經實現大部分覆蓋,但是基層終端覆蓋率仍然較低;開喉劍噴霧劑成人型是18年才進入國家醫保目錄的,起步較晚,因此醫院覆蓋率還比較低,後續整體提升空間較大。總體來説,開喉劍系列產品目前在處方端和OTC端的佔比大概在5:5這樣一個區間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.